EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
8.35
-0.61 (-6.76%)
Nov 21, 2024, 4:00 PM EST - Market closed
EyePoint Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 45.71 | 46.02 | 41.4 | 36.94 | 34.44 | 20.37 | Upgrade
|
| Revenue Growth (YoY) | 7.50% | 11.14% | 12.09% | 7.27% | 69.10% | 345.53% | Upgrade
|
| Cost of Revenue | 110.2 | 68.99 | 57.97 | 36.07 | 23.25 | 18.06 | Upgrade
|
| Gross Profit | -64.49 | -22.98 | -16.56 | 0.87 | 11.19 | 2.31 | Upgrade
|
| Selling, General & Admin | 51.28 | 50.89 | 60.32 | 53.68 | 46.02 | 47.71 | Upgrade
|
| Operating Expenses | 51.28 | 50.89 | 62.37 | 56.14 | 48.48 | 50.17 | Upgrade
|
| Operating Income | -115.77 | -73.87 | -78.94 | -55.28 | -37.29 | -47.86 | Upgrade
|
| Interest Expense | - | -1.25 | -3.19 | -5.5 | -7.26 | -6.18 | Upgrade
|
| Interest & Investment Income | 13.48 | 6.95 | 2.13 | 0.29 | 0.06 | 1.05 | Upgrade
|
| EBT Excluding Unusual Items | -102.29 | -68.16 | -80 | -60.48 | -44.49 | -52.98 | Upgrade
|
| Merger & Restructuring Charges | -1.2 | -1.2 | - | - | - | - | Upgrade
|
| Asset Writedown | - | - | -20.7 | - | - | - | Upgrade
|
| Other Unusual Items | - | -1.35 | -1.56 | 2.07 | -0.91 | -3.81 | Upgrade
|
| Pretax Income | -103.49 | -70.71 | -102.25 | -58.42 | -45.39 | -56.79 | Upgrade
|
| Income Tax Expense | 0.08 | 0.08 | - | - | - | - | Upgrade
|
| Net Income | -103.57 | -70.8 | -102.25 | -58.42 | -45.39 | -56.79 | Upgrade
|
| Net Income to Common | -103.57 | -70.8 | -102.25 | -58.42 | -45.39 | -56.79 | Upgrade
|
| Shares Outstanding (Basic) | 51 | 39 | 37 | 29 | 13 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 51 | 39 | 37 | 29 | 13 | 10 | Upgrade
|
| Shares Change (YoY) | 34.50% | 4.25% | 29.76% | 124.04% | 23.06% | 53.88% | Upgrade
|
| EPS (Basic) | -2.04 | -1.82 | -2.74 | -2.03 | -3.54 | -5.44 | Upgrade
|
| EPS (Diluted) | -2.04 | -1.82 | -2.74 | -2.03 | -3.54 | -5.44 | Upgrade
|
| Free Cash Flow | -118.04 | -1.61 | -67.16 | -50.25 | -14.8 | -56.91 | Upgrade
|
| Free Cash Flow Per Share | -2.33 | -0.04 | -1.80 | -1.75 | -1.15 | -5.46 | Upgrade
|
| Gross Margin | -141.06% | -49.93% | -40.01% | 2.35% | 32.49% | 11.34% | Upgrade
|
| Operating Margin | -253.25% | -160.52% | -190.65% | -149.64% | -108.28% | -235.02% | Upgrade
|
| Profit Margin | -226.57% | -153.84% | -246.97% | -158.14% | -131.82% | -278.88% | Upgrade
|
| Free Cash Flow Margin | -258.21% | -3.49% | -162.19% | -136.04% | -42.97% | -279.46% | Upgrade
|
| EBITDA | -114.58 | -73.4 | -76.49 | -52.51 | -34.64 | -45.26 | Upgrade
|
| EBITDA Margin | -250.66% | -159.51% | -184.75% | -142.14% | -100.59% | -222.23% | Upgrade
|
| D&A For EBITDA | 1.19 | 0.46 | 2.45 | 2.77 | 2.65 | 2.6 | Upgrade
|
| EBIT | -115.77 | -73.87 | -78.94 | -55.28 | -37.29 | -47.86 | Upgrade
|
| EBIT Margin | -253.25% | -160.52% | -190.65% | -149.64% | -108.28% | -235.02% | Upgrade
|
| Revenue as Reported | 45.71 | 46.02 | 41.4 | 36.94 | 34.44 | 20.37 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.